| Pharmaceutical Information |
| Drug Name |
Peginesatide |
| Drug ID |
BADD_D01694 |
| Description |
Peginesatide is a synthetic peptide attached to polyethylene glycol for the treatment of anemia. The polyethylene glycol moiety helps make the drug less immunogenic and prolongs its plasma half-life. Chemically, peginesatide is designed to mimic the pharmacological activity of erythropoietin, but is not a replica of the structure itself. Peginesatide consists of two 21-amino acid chains that are covalently bonded by a linker derived from iminodiacetic acid and β-alanine. FDA approved March 27, 2012. |
| Indications and Usage |
Peginesatide is used for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis |
| Marketing Status |
Not Available |
| ATC Code |
B03XA04 |
| DrugBank ID |
DB08894
|
| KEGG ID |
D09946
|
| MeSH ID |
C556270
|
| PubChem ID |
Not Available
|
| TTD Drug ID |
Not Available
|
| NDC Product Code |
Not Available |
| Synonyms |
peginesatide | AF-37702 | AF 37702 |
|
| Chemical Information |
| Molecular Formula |
Not Available |
| CAS Registry Number |
913976-27-9 |
| SMILES |
Not Available |
| Chemical Structure |
|
|
| ADR Related Proteins Induced by Drug |
| ADR Term |
Protein Name |
UniProt AC |
TTD Target ID |
PMID |
| Not Available | Not Available | Not Available | Not Available | Not Available |
|
| ADRs Induced by Drug |
|
|
